Novel Blood Thinner Asundexian Lowers Bleeding Risk in Atrial Fibrillation
New findings from the OCEANIC-AF trial reveal trade-offs between stroke prevention and bleeding risk in treatment-naive patients
Topline:
A new oral blood thinner, asundexian, may reduce bleeding risk in patients with atrial fibrillation who have not previously taken anticoagulants, though it shows a slightly higher rate of stroke compared to apixaban.
Study Details
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.